Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20330475 | 0.87 | GAA (0.32) | MEN1KMT2AGAA | |
| SCHEMBL22794331 | 0.84 | MAPK1 (0.37) | KDM4EALDH1A1HRH3MEN1KMT2A | |
| SCHEMBL26224162 | 0.84 | MAPK1 (0.37) | KDM4EALDH1A1HRH3MEN1KMT2A | |
| SCHEMBL25479251 | 0.84 | MAPK1 (0.37) | KDM4EALDH1A1HRH3MEN1KMT2A | |
| SCHEMBL24513936 | 0.84 | KDM4E (0.33) | KDM4EALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL20330477 | 0.83 | KDM4E (0.36) | KDM4EALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL24654362 | 0.83 | KDM4E (0.38) | KDM4EALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL18592280 | 0.81 | KDM4E (0.37) | KDM4EALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL21664661 | 0.80 | HRH3 (0.37) | KDM4EALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL21026059 | 0.80 | KDM4E (0.39) | KDM4EALDH1A1CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | KDM4E 713/4885ALDH1A1 824/4885CYP1A2 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.